{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:55:07Z","timestamp":1793382907989,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40259-018-0295-0","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:25:57Z","timestamp":1532391957000},"page":"425-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":435,"title":["Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities"],"prefix":"10.1007","volume":"32","author":[{"given":"Beate","family":"Bittner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"295_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0091270012436560","volume":"53","author":"C Wynne","year":"2013","unstructured":"Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I\/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol. 2013;53:192\u2013201.","journal-title":"J Clin Pharmacol"},{"key":"295_CR2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.18553\/jmcp.2008.14.9.844","volume":"14","author":"GB Kruse","year":"2008","unstructured":"Kruse GB, Amonkar MM, Smith G, Skonieczny DC, Stavrakas S. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008;14:844\u201357.","journal-title":"J Manag Care Pharm."},{"key":"295_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/annonc\/mdm272","volume":"19","author":"S Vescia","year":"2008","unstructured":"Vescia S, Baumgartner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S, et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol. 2008;19:9\u201315.","journal-title":"Ann Oncol"},{"key":"295_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13561-014-0026-2","volume":"4","author":"EK Tetteh","year":"2014","unstructured":"Tetteh EK, Morris S. Evaluating the administration costs of biologic drugs: development of a cost algorithm. Health Econ Rev. 2014;4:26.","journal-title":"Health Econ Rev"},{"key":"295_CR5","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","volume":"25","author":"X Pivot","year":"2014","unstructured":"Pivot X, Gligorov J, Muller V, Curigliano G, Knoop A, Verma S, et al. Patients\u2019 preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25:1979\u201387.","journal-title":"Ann Oncol"},{"key":"295_CR6","doi-asserted-by":"crossref","unstructured":"De Cock E, Kritikou P, Tao S, Waterboer T, Carella AM. Time savings with rituximab subcutaneous (SC) injection vs rituximab intravenous (IV) infusion: final analysis from a time-and-motion study in 8 countries. Am Soc Hematology. In: 55th Annual meeting and exposition, New Orleans; 2012.","DOI":"10.1182\/blood.V122.21.1724.1724"},{"key":"295_CR7","doi-asserted-by":"publisher","first-page":"A653","DOI":"10.1016\/j.jval.2014.08.2380","volume":"17","author":"E Cock De","year":"2014","unstructured":"De Cock E, Pan YI, Tao S, Baidin P. Time savings with trastuzumab subcutaneous (SC) injection verse trastuzumab intravenous (IV) infusion: a time and motion study in 3 russian centers. Value Health. 2014;17:A653.","journal-title":"Value Health"},{"key":"295_CR8","doi-asserted-by":"publisher","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","volume":"11","author":"E Cock De","year":"2016","unstructured":"De Cock E, Kritikou P, Sandoval M, Tao S, Wiesner C, Carella AM, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11:e0157957.","journal-title":"PLoS One"},{"key":"295_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14:559\u201370.","journal-title":"AAPS J"},{"key":"295_CR10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1124\/dmd.114.059238","volume":"42","author":"WF Richter","year":"2014","unstructured":"Richter WF, Jacobsen B. Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 2014;42:1881\u20139.","journal-title":"Drug Metab Dispos"},{"key":"295_CR11","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","volume":"106","author":"L Hamuro","year":"2017","unstructured":"Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu DX, Zepeda M, et al. Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. J Pharm Sci. 2017;106:2946\u201354.","journal-title":"J Pharm Sci"},{"key":"295_CR12","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/bjc.2013.371","volume":"109","author":"O Shpilberg","year":"2013","unstructured":"Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013;109:1556\u201361.","journal-title":"Br J Cancer"},{"key":"295_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","volume":"21","author":"A Gardulf","year":"2007","unstructured":"Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105\u201316.","journal-title":"BioDrugs"},{"key":"295_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2249.2009.04079.x","volume":"160","author":"J Beaute","year":"2010","unstructured":"Beaute J, Levy P, Millet V, Debre M, Dudoit Y, Le Mignot L, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160:240\u20135.","journal-title":"Clin Exp Immunol"},{"key":"295_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.COT.0000524502.41911.56","volume":"39","author":"C Bennett","year":"2017","unstructured":"Bennett C. At-home subcutaneous injection of trastuzumab meets safety endpoint. Oncol Times. 2017;39:26\u20137.","journal-title":"Oncol Times"},{"key":"295_CR16","first-page":"51","volume":"9","author":"W Tjalma","year":"2017","unstructured":"Tjalma W, Huizing M, Papadimitriou K. The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home. Facts Views Vis ObGyn. 2017;9:51\u20135.","journal-title":"Facts Views Vis ObGyn"},{"key":"295_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejpb.2017.06.029","volume":"119","author":"P Garidel","year":"2017","unstructured":"Garidel P, Kuhn AB, Schafer LV, Karow-Zwick AR, Blech M. High-concentration protein formulations: how high is high? Eur J Pharm Biopharm. 2017;119:353\u201360.","journal-title":"Eur J Pharm Biopharm"},{"key":"295_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1517\/17425247.4.4.427","volume":"4","author":"GI Frost","year":"2007","unstructured":"Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4:427\u201340.","journal-title":"Expert Opin Drug Deliv"},{"key":"295_CR19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/imt-2017-0092","volume":"9","author":"RL Wasserman","year":"2017","unstructured":"Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy. 2017;9:1035\u201350.","journal-title":"Immunotherapy"},{"key":"295_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0091270009337512","volume":"49","author":"DD Wang","year":"2009","unstructured":"Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49:1012\u201324.","journal-title":"J Clin Pharmacol"},{"key":"295_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","volume":"15","author":"A Davies","year":"2014","unstructured":"Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Celigny P, Barrett M, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15:343\u201352.","journal-title":"Lancet Oncol"},{"key":"295_CR22","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1038\/psp.2013.63","volume":"3","author":"F Hourcade-Potelleret","year":"2014","unstructured":"Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C, Brewster M, Lum B, Bittner B. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacomet Syst Pharmacol. 2014;3:e87.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"295_CR23","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","volume":"22","author":"J Hendrikx","year":"2017","unstructured":"Hendrikx J, Haanen J, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22:1212\u201321.","journal-title":"Oncologist"},{"key":"295_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ctrv.2015.10.008","volume":"41","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev. 2015;41:859\u201367.","journal-title":"Cancer Treat Rev"},{"key":"295_CR25","first-page":"368","volume":"35","author":"F Angelotti","year":"2017","unstructured":"Angelotti F, Parma A, Cafaro G, Capecchi R, Alunno A, Puxeddu I. One year in review 2017: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2017;35:368\u201378.","journal-title":"Clin Exp Rheumatol"},{"key":"295_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369\u201395.","journal-title":"J Intern Med"},{"key":"295_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1586\/1744666X.2016.1155452","volume":"12","author":"H Shabaninejad","year":"2016","unstructured":"Shabaninejad H, Asgharzadeh A, Rezaei N, Rezapoor A. A comparative study of intravenous immunoglobulin and subcutaneous immunoglobulin in adult patients with primary immunodeficiency diseases: a systematic review and meta-analysis. Expert Rev Clin Immunol. 2016;12:595\u2013602.","journal-title":"Expert Rev Clin Immunol"},{"key":"295_CR28","first-page":"277","volume":"6","author":"L Kobrynski","year":"2012","unstructured":"Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277\u201387.","journal-title":"Biologics"},{"key":"295_CR29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139:S1\u201346.","journal-title":"J Allergy Clin Immunol"},{"key":"295_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1080\/14740338.2017.1388371","volume":"16","author":"F Auricchio","year":"2017","unstructured":"Auricchio F, Scavone C, Cimmaruta D, Di Mauro G, Capuano A, Sportiello L, et al. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf. 2017;16:1359\u201371.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"295_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","volume":"29","author":"A Rotte","year":"2018","unstructured":"Rotte A, Jin J, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71\u201383.","journal-title":"Ann Oncol"},{"key":"295_CR32","first-page":"401","volume":"62","author":"B Bittner","year":"2012","unstructured":"Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, et al. Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Drug Res (Stuttg). 2012;62:401\u20139.","journal-title":"Drug Res (Stuttg)"},{"key":"295_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1055\/s-0033-1363993","volume":"64","author":"B Bittner","year":"2014","unstructured":"Bittner B, Richter WF, Hourcade-Potelleret F, Herting F, Schmidt J. Non-clinical pharmacokinetic\/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg). 2014;64:569\u201375.","journal-title":"Drug Res (Stuttg)"},{"key":"295_CR34","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319\u201331.","journal-title":"N Engl J Med"},{"key":"295_CR35","unstructured":"Janssen Research & Development L. A study of subcutaneous versus (vs.) intravenous administration of daratumumab in participants with relapsed or refractory multiple myeloma; 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03277105 . Accessed 31 Mar 2018."},{"key":"295_CR36","unstructured":"Janssen Research & Development L. A study of subcutaneous daratumumab versus active monitoring in participants with high-risk smoldering multiple myeloma. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03301220 . Accessed 31 Mar 2018."},{"key":"295_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1055\/s-0035-1546172","volume":"75","author":"C Jackisch","year":"2015","unstructured":"Jackisch C, Muller V, Dall P, Neumeister R, Park-Simon TW, Ruf-Dordelmann A, et al. Subcutaneous trastuzumab for her2-positive breast cancer\u2014evidence and practical experience in 7 german centers. Geburtshilfe Frauenheilkd. 2015;75:566\u201373.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"295_CR38","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Gligorov J, Muller V, Barrett-Lee P, Verma S, Knoop A, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962\u201370.","journal-title":"Lancet Oncol"},{"key":"295_CR39","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","volume":"13","author":"G Ismael","year":"2012","unstructured":"Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869\u201378.","journal-title":"Lancet Oncol"},{"key":"295_CR40","doi-asserted-by":"crossref","unstructured":"Pivot X, Semiglazov V, Chen S, Moodley S, Manihkas A, Coccia-Portugal M et al. Subcutaneous injection of trastuzumab\u2014analysis of administration time and injection site reactions. ESMO 2012.","DOI":"10.1016\/S0923-7534(20)32834-9"},{"key":"295_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cam4.573","volume":"5","author":"E Cock De","year":"2016","unstructured":"De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5:389\u201397.","journal-title":"Cancer Med"},{"key":"295_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4236\/abcr.2013.24022","volume":"2","author":"R Burcombe","year":"2013","unstructured":"Burcombe R, Chan S, Simcock R, Samanta K, Percival F, Barrett-Lee P. Subcutaneous trastuzumab (Herceptin\u00ae): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Cancer Res. 2013;2:133\u201340.","journal-title":"Adv Breast Cancer Res"},{"key":"295_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejogrb.2017.12.006","volume":"221","author":"W Tjalma","year":"2018","unstructured":"Tjalma W, Van den Mooter T, Mertens T, Bastiaens V, Huizing M. PapadimitriounK. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit. Eur J Obstet Gynecol Reprod Biol. 2018;221:46\u201351.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"295_CR44","doi-asserted-by":"publisher","first-page":"A418","DOI":"10.1016\/j.jval.2013.08.546","volume":"16","author":"S Andrade","year":"2013","unstructured":"Andrade S, Santos A. Hospital resources consumption associated with trastuzumab treatment in breast cancer in portugal. Value Health. 2013;16:A418.","journal-title":"Value Health"},{"key":"295_CR45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bulcan.2015.01.007","volume":"102","author":"V Lieutenant","year":"2015","unstructured":"Lieutenant V, Toulza E, Pommier M. Lortal-Canguilhem B [Is Herceptin(\u00ae) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study]. Bull Cancer. 2015;102:270\u20136.","journal-title":"Bull Cancer"},{"key":"295_CR46","doi-asserted-by":"publisher","first-page":"A640","DOI":"10.1016\/j.jval.2014.08.2310","volume":"17","author":"C Mylonas","year":"2014","unstructured":"Mylonas C, Kourlaba G, Fountzilas G, Skroumpelos A, Maniadakis N. Cost-minimization analysis of trastuzumab intravenous versus trastuzumab subcutaneous for the treatment of patients with HER2+ early breast cancer and metastatic breast cancer in Greece. Value Health. 2014;17:A640\u20131.","journal-title":"Value Health"},{"key":"295_CR47","unstructured":"De Cock E, Semiglazov V, Lopez Vivanco G, Verma S, Pivot X, Gligorov J et al. Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study. St. Gallen 2013, Abstr. P209"},{"key":"295_CR48","unstructured":"De Cock E, Pan I, Sandoval M, Millar D, Knoop A. Healthcare professionals\u2019 perceptions of the impact on clinical management of switching from the intravenous to the subcutaneous formulation of trastuzumab. In: European breast cancer conference 2014, Glasgow, Abstr. 42"},{"key":"295_CR49","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1182\/blood-2006-11-059469","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood. 2007;109:4171\u20133.","journal-title":"Blood"},{"key":"295_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1586\/17474086.2015.1024651","volume":"8","author":"P Solal-Celigny","year":"2015","unstructured":"Solal-Celigny P. Rituximab by subcutaneous route. Expert Rev Hematol. 2015;8:147\u201353.","journal-title":"Expert Rev Hematol"},{"key":"295_CR51","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3111\/13696998.2014.914033","volume":"17","author":"S Rule","year":"2014","unstructured":"Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17:459\u201368.","journal-title":"J Med Econ"},{"key":"295_CR52","doi-asserted-by":"publisher","first-page":"A207","DOI":"10.1016\/j.jval.2015.03.1200","volume":"18","author":"SS Ariza","year":"2015","unstructured":"Ariza SS. Time and motion study for rituximab SC vs IV in Colombian patients with non-Hodgkin lymphoma. Value Health. 2015;18:A207.","journal-title":"Value Health"},{"key":"295_CR53","doi-asserted-by":"publisher","first-page":"A390","DOI":"10.1016\/j.jval.2013.08.392","volume":"16","author":"P Bax","year":"2013","unstructured":"Bax P, Postma M. Cost-minimization of mabthera intravenous versus subcutaneous administration. Value Health. 2013;16:A390\u20131.","journal-title":"Value Health"},{"key":"295_CR54","doi-asserted-by":"publisher","first-page":"A386","DOI":"10.1016\/j.jval.2013.08.366","volume":"16","author":"C Pereira","year":"2013","unstructured":"Pereira C, Santos A. Resource consumption evaluation associated with rituximab administration in Portugal. Value Health. 2013;16:A386.","journal-title":"Value Health"},{"key":"295_CR55","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","volume":"28","author":"M Rummel","year":"2017","unstructured":"Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28:836\u201342.","journal-title":"Ann Oncol"},{"key":"295_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40261-015-0270-1","volume":"35","author":"A Vultaggio","year":"2015","unstructured":"Vultaggio A, Azzari C, Milito C, Finocchi A, Toppino C, Spadaro G, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig. 2015;35:179\u201385.","journal-title":"Clin Drug Investig"},{"key":"295_CR57","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","volume":"32","author":"H Abolhassani","year":"2012","unstructured":"Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32:1180\u201392.","journal-title":"J Clin Immunol"},{"key":"295_CR58","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.clinthera.2014.08.007","volume":"36","author":"A Igarashi","year":"2014","unstructured":"Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Clin Ther. 2014;36:1616\u201324.","journal-title":"Clin Ther"},{"key":"295_CR59","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s40265-013-0094-3","volume":"73","author":"J Lingman-Framme","year":"2013","unstructured":"Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73:1307\u201319.","journal-title":"Drugs"},{"key":"295_CR60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5731\/pdajpst.2015.01003","volume":"69","author":"B Gikanga","year":"2015","unstructured":"Gikanga B, Turok R, Hui A, Bowen M, Stauch OB, Maa YF. Manufacturing of high-concentration monoclonal antibody formulations via spray drying-the road to manufacturing scale. PDA J Pharm Sci Technol. 2015;69:59\u201373.","journal-title":"PDA J Pharm Sci Technol"},{"key":"295_CR61","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722\u20138.","journal-title":"Pediatrics"},{"key":"295_CR62","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10875-009-9352-2","volume":"30","author":"R Shapiro","year":"2010","unstructured":"Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010;30:301\u20137.","journal-title":"J Clin Immunol"},{"key":"295_CR63","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","volume":"114","author":"LH Bookbinder","year":"2006","unstructured":"Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114:230\u201341.","journal-title":"J Control Release"},{"key":"295_CR64","unstructured":"U.S. Food and Drug Administration; 2018. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm . Accessed 31 Mar 2018."},{"key":"295_CR65","unstructured":"The Electronic Medicines Compendium; 2018. https:\/\/www.medicines.org.uk\/emc\/about-the-emc . Accessed 31 Mar 2018."},{"key":"295_CR66","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","volume":"36","author":"RL Wasserman","year":"2016","unstructured":"Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, et al. Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J Clin Immunol. 2016;36:571\u201382.","journal-title":"J Clin Immunol"},{"key":"295_CR67","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1208\/s12249-015-0288-y","volume":"16","author":"C Dias","year":"2015","unstructured":"Dias C, Abosaleem B, Crispino C, Gao B, Shaywitz A. Tolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjects. AAPS PharmSciTech. 2015;16:1101\u20137.","journal-title":"AAPS PharmSciTech"},{"key":"295_CR68","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1177\/1932296815626723","volume":"10","author":"KA Praestmark","year":"2016","unstructured":"Praestmark KA, Stallknecht B, Jensen ML, Sparre T, Madsen NB, Kildegaard J. Injection technique and pen needle design affect leakage from skin after subcutaneous injections. J Diabetes Sci Technol. 2016;10:914\u201322.","journal-title":"J Diabetes Sci Technol"},{"key":"295_CR69","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.xphs.2016.04.009","volume":"105","author":"DV Doughty","year":"2016","unstructured":"Doughty DV, Clawson CZ, Lambert W, Subramony JA. Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery. J Pharm Sci. 2016;105:2105\u201313.","journal-title":"J Pharm Sci"},{"key":"295_CR70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","volume":"2","author":"DN McLennan","year":"2005","unstructured":"McLennan DN, Porter CJ, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol. 2005;2:89\u201396.","journal-title":"Drug Discov Today Technol"},{"key":"295_CR71","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1015880819328","volume":"7","author":"A Supersaxo","year":"1990","unstructured":"Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7:167\u20139.","journal-title":"Pharm Res"},{"key":"295_CR72","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0378-5173(94)90103-1","volume":"105","author":"J Zuidema","year":"1994","unstructured":"Zuidema J, Kadir F, Titulaer H, Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm. 1994;105:189\u2013207.","journal-title":"Int J Pharm"},{"key":"295_CR73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0169-409X(95)00045-9","volume":"17","author":"A Hawley","year":"1995","unstructured":"Hawley A, Davis S, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev. 1995;17:129\u201348.","journal-title":"Adv Drug Deliv Rev"},{"key":"295_CR74","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","volume":"4","author":"A Davies","year":"2017","unstructured":"Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4:e272\u201382.","journal-title":"Lancet Haematol"},{"key":"295_CR75","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdh176","volume":"15","author":"K Tobinai","year":"2004","unstructured":"Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004;15:821\u201330.","journal-title":"Ann Oncol"},{"key":"295_CR76","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719\u201326.","journal-title":"J Clin Oncol"},{"key":"295_CR77","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601\u20139.","journal-title":"Oncologist"},{"key":"295_CR78","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725\u201332.","journal-title":"Oncologist"},{"key":"295_CR79","doi-asserted-by":"publisher","first-page":"e80533","DOI":"10.1371\/journal.pone.0080533","volume":"8","author":"CP Mao","year":"2013","unstructured":"Mao CP, Brovarney MR, Dabbagh K, Birnbock HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One. 2013;8:e80533.","journal-title":"PLoS One"},{"key":"295_CR80","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/2040620712458949","volume":"3","author":"JL Warner","year":"2012","unstructured":"Warner JL, Arnason JE. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol. 2012;3:375\u201389.","journal-title":"Ther Adv Hematol"},{"key":"295_CR81","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768\u201373.","journal-title":"Blood"},{"key":"295_CR82","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani SZ, Nahi H, Mateos M-V, Lokhorst HM, Chari A, Kaufman JL, et al. Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO). Blood. 2016;128:1149.","journal-title":"Blood"},{"key":"295_CR83","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","volume":"15","author":"AM Fathallah","year":"2013","unstructured":"Fathallah AM, Bankert RB, Balu-Iyer SV. Immunogenicity of subcutaneously administered therapeutic proteins-a mechanistic perspective. AAPS J. 2013;15:897\u2013900.","journal-title":"AAPS J"},{"key":"295_CR84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0923-7534(20)32835-0","volume":"23","author":"R Hegg","year":"2012","unstructured":"Hegg R, Pienkowski T, Chen S, Staroslawska E, Falcon S, Kovalenko N, et al. Immunogenicity of trastuzumab intravenous and subcutaneous formulations in the Phase III HannaH study. Ann Oncol. 2012;23:103.","journal-title":"Ann Oncol"},{"key":"295_CR85","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/art.30463","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63:2854\u201364.","journal-title":"Arthritis Rheum"},{"key":"295_CR86","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","volume":"66","author":"A Ogata","year":"2014","unstructured":"Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:344\u201354.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"295_CR87","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.dmpk.2017.05.002","volume":"32","author":"K Haraya","year":"2017","unstructured":"Haraya K, Tachibana T, Nezu J. Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metab Pharmacokinet. 2017;32(4):208\u201317.","journal-title":"Drug Metab Pharmacokinet"},{"key":"295_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1458808","author":"WF Richter","year":"2018","unstructured":"Richter WF, Christianson GJ, Frances N, Grimm HP, Proetzel G, Roopenian DC. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. MAbs. 2018. https:\/\/doi.org\/10.1080\/19420862.2018.1458808 .","journal-title":"MAbs"},{"issue":"951\u20137","key":"295_CR89","first-page":"e11","volume":"130","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(951\u20137):e11.","journal-title":"J Allergy Clin Immunol"},{"key":"295_CR90","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5414\/CP201847","volume":"51","author":"PN Morcos","year":"2013","unstructured":"Morcos PN, Zhang X, McIntyre C, Bittner B, Rowell L, Hussain Z. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int J Clin Pharmacol Ther. 2013;51:537\u201348.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"295_CR91","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1089\/dia.2011.0117","volume":"14","author":"M Hompesch","year":"2012","unstructured":"Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther. 2012;14:218\u201324.","journal-title":"Diabetes Technol Ther"},{"key":"295_CR92","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0091270009340782","volume":"50","author":"Z Xu","year":"2010","unstructured":"Xu Z, Wang Q, Zhuang Y, Frederick B, Yan H, Bouman-Thio E, et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol. 2010;50:276\u201384.","journal-title":"J Clin Pharmacol"},{"key":"295_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/cpdd.60","volume":"3","author":"H Ortega","year":"2013","unstructured":"Ortega H, Yancey S, Cozens S. Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites. Clin Pharmacol Drug Dev. 2013;3:57\u201362.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-018-0295-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T22:56:57Z","timestamp":1661641017000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-018-0295-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0295-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]},"assertion":[{"value":"24 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Support for third party medical writing assistance for this manuscript was provided by F. Hoffmann La Roche Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Beate Bittner, Wolfgang Richter, and Johannes Schmidt are employees of F. Hoffmann La Roche and own stock in Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}